AcquisitionsJul 29, 2026, 04:09 PM
Teva Completes Emalex Acquisition for $700M; Reports Q2 Net Loss
AI Summary
Teva Pharmaceutical Industries Ltd. completed the acquisition of Emalex Biosciences for approximately $700 million in June 2026, significantly impacting its second-quarter financial results. The company reported a net loss attributable to Teva of $576 million for Q2 2026, a decrease from a net income of $282 million in the prior year, largely due to $724 million in acquired in-process R&D expenses related to the acquisition. Net revenues for the quarter were $4,142 million, a slight decline year-over-year.
Key Highlights
- Completed acquisition of Emalex Biosciences for approximately $700 million in June 2026.
- Reported Q2 2026 net loss attributable to Teva of $576 million.
- Basic loss per share for Q2 2026 was $0.49.
- Net revenues for Q2 2026 were $4,142 million, down from $4,176 million YoY.
- R&D expenses surged to $970 million in Q2 2026, including $724 million for acquired IPR&D.
- Net cash provided by operating activities was $411 million in Q2 2026.
- Short-term debt increased to $4,500 million as of June 30, 2026.
Price Impact
More from TEVA